The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
Open accessAbstract
Background Bruton tyrosine kinase is a clinically validated target in mantle cell lymphoma. Acalabrutinib (ACP-196) is a highly selective, potent Bruton tyrosine kinase inhibitor developed to minimise off-target activity.Methods In this open-label, phase 2 study, oral acalabrutinib (100 mg twice per day) was given to patients with relapsed or refractory mantle cell lymphoma, until disease progression or unacceptable toxicity. The primary endpoint was overall response assessed according to the Lugano classification, and safety analyses were done in all participants. This trial is registered with ClinicalTrials.gov, number NCT02213926.Findings From March 12, 2015, to Jan 5, 2016, 124 patients with relapsed or refractory mantle cell lymphoma were enrolled and all patients received treatment; median age 68 years. Patients received a median of two (IQR 1-2) previous therapies. At a median follow-up of 15·2 months, 100 (81%) patients achieved an overall response and 49 (40%) patients achieved a complete response. The Kaplan-Meier estimated medians for duration of response, progression-free survival, and overall survival were not reached; the 12-month rates were 72% (95% CI 62-80), 67% (58-75), and 87% (79-92%), respectively. The most common adverse events were primarily grade 1 or 2 and were headache (47 [38%]), diarrhoea (38 [31%]), fatigue (34 [27%]), and myalgia (26 [21%]). The most common grade 3 or worse adverse events were neutropenia (13 [10%]), anaemia (11 [9%]), and pneumonia (six [5%]). There were no cases of atrial fibrillation and one case of grade 3 or worse haemorrhage. The median duration of treatment was 13·8 months. Treatment was discontinued in 54 (44%) patients, primarily due to progressive disease (39 [31%]) and adverse events (seven [6%]).Interpretation Acalabrutinib treatment provided a high rate of durable responses and a favourable safety profile in patients with relapsed or refractory mantle cell lymphoma. These findings suggest an important role for acalabrutinib in the treatment of this disease population.Funding Acerta Pharma, a member of the AstraZeneca Group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As such, ibrutinib and the more selective BTK inhibitor acalabrutinib 39 have shown beneficial effects in patients with MCL and have received US Food and Drug Administration approval for this indication.”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Self-citationAcalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Harrington, B. K., O'Brien, S. M., Jones, J. A., Schuh, A., Devereux, S., Chaves, J. M., Wierda, W. G., Awan, F. T., Brown, J. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509981 · Cited by 916
Ponader, S., Chen, S.-S., Buggy, J. J., Balakrishnan, K., Gandhi, V., Wierda, W. G., Keating, M. J., O'Brien, S., Chiorazzi, N., & Burger, J. A. (2012) · Blood · doi:10.1182/blood-2011-10-386417 · Cited by 640
de Rooij, M. F. M., Kuil, A., Geest, C. R., Eldering, E., Chang, B. Y., Buggy, J. J., Pals, S. T., & Spaargaren, M. (2012) · Blood · doi:10.1182/blood-2011-11-390989 · Cited by 558
Barf, T. A., Covey, T. M., Izumi, R. E., van de Kar, B., Gulrajani, M., van Lith, B., Hoek, M. E.-V., de Zwart, E., Mittag, D., Demont, D., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.242909 · Cited by 399
Cheah, C. Y., Seymour, J. F., & Wang, M. L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5904 · Cited by 276
Cited by
Sorted by citations
Items 201–300 of 461
Jiang, Z., Shi, L., Zhang, Y., Lin, G., & Wang, Y. (2020) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113613 · Cited by 12
Wu, H., Wang, J., Zhang, X., Yang, H., Wang, Y., Sun, P., Cai, Q., Xia, Y., & Liu, P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.588314 · Cited by 12
Mantle cell lymphoma—Advances in molecular biology, prognostication and treatment approaches
Silkenstedt, E., & Dreyling, M. H. (2021) · Hematological Oncology · doi:10.1002/hon.2860 · Cited by 12
Girard, J., Reneau, J. C., Devata, S., Wilcox, R. A., Kaminski, M. S., Mercer, J., Carty, S. A., & Phillips, T. J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s155778 · Cited by 12
Acalabrutinib for adults with mantle cell lymphoma
Jurczak, W. J., Długosz‐Danecka, M., & Wang, M. L. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1568868 · Cited by 11
Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase Inhibitors
Aghel, N., Vila, R. C. B., Lui, M., Hillis, C., & Leong, D. P. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01916-4 · Cited by 12
The role of acalabrutinib in adults with chronic lymphocytic leukemia
Fakhri, B., & Andreadis, C. B. (2021) · Therapeutic Advances in Hematology · doi:10.1177/2040620721990553 · Cited by 11
Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma
Ahmed, M., Lorence, E., Wang, J., Jung, D., Zhang, L., Nomie, K. J., & Wang, M. L. (2019) · Science Signaling · doi:10.1126/scisignal.aat4105 · Cited by 12
Molecular profiling and management of mantle cell lymphoma
Ruan, J. (2019) · Hematology · doi:10.1182/hematology.2019000011 · Cited by 11
Infectious Complications of Tyrosine Kinase Inhibitors in Hematological Malignancies
Kin, A. D., & Schiffer, C. A. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.02.008 · Cited by 11
Dreyling, M. H., Doorduijn, J., Giné, E., Jerkeman, M., Walewski, J., Hutchings, M., Mey, U., Riise, J., Trneny, M., Vergote, V. K. J., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00362-4 · Cited by 11
Advances in Classification and Treatment of Non-Hodgkin Lymphoma
Rule, S. A., & Johns, S. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000462 · Cited by 10
Jiang, C., Lee, W., Zhang, T., Jordan, A. A., Yan, F., Cai, Q., McIntosh, J. M., Vargas, J., Liu, Y., & Wang, M. L. (2024) · Biomarker Research · doi:10.1186/s40364-024-00589-7 · Cited by 10
Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib
Broccoli, A., Re, M. D., Danesi, R., & Zinzani, P. L. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70170 · Cited by 12
Park, H. Y., Chae, M. K., Ko, J., Kikkawa, D. O., Jang, S. Y., & Yoon, J. S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279060 · Cited by 10
Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma
Karmali, R., Abramson, J. S., Stephens, D. M., Barnes, J. A., Winter, J. N., Ma, S., Gao, J., Kaplan, J. B., Petrich, A. M., Hochberg, E. P., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011271 · Cited by 10
Acalabrutinib in mantle cell lymphoma
Kapoor, P., & Ansell, S. M. (2017) · The Lancet · doi:10.1016/s0140-6736(17)33256-7 · Cited by 9
Ratnasingam, S., Casan, J. M. L., Shortt, J., Hawkes, E. A., Gilbertson, M., McQuilten, Z., Grigoriadis, G., Htun, K., Htet, S. M., Campbell, P. J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-49776-9 · Cited by 10
The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients
Derebas, J., Panuciak, K., Margas, M., Zawitkowska, J., & Lejman, M. (2022) · Cancers · doi:10.3390/cancers14061569 · Cited by 11
Izutsu, K., Ando, K., Ennishi, D., Shibayama, H., Suzumiya, J., Yamamoto, K., Ichikawa, S., Kato, K., Kumagai, K., Patel, P. S., et al. (2021) · Cancer Science · doi:10.1111/cas.14886 · Cited by 10
Liebers, N., Boumendil, A., Finel, H., Edelmann, D., Kobbe, G., Baermann, B., Serroukh, Y. I. M., Blaise, D., Beelen, D. W., Solano, C., et al. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0178 · Cited by 9
Use of acalabrutinib in patients with mantle cell lymphoma
Awan, F. T., & Jurczak, W. J. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1473030 · Cited by 9
Yeung, C. C. S., & Shadman, M. S. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0819-x · Cited by 10
Collins, G. P., Clevenger, T. N., Burke, K. A., Buyue, Y., MacDonald, A., Cunningham, D., Fox, C. P., Goy, A. H., Gribben, J. G., Nowakowski, G. S., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1938027 · Cited by 9
Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: A systemic review
Salter, B., Burns, I., Fuller, K., Eshaghpour, A., Lionel, A. C., & Crowther, M. A. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13786 · Cited by 9
Di, M., Long, J. B., Kothari, S. K., Sethi, T. K., Zeidan, A. M., Podoltsev, N. A., Shallis, R. M., Wang, R., Ma, X., & Huntington, S. F. (2023) · Haematologica · doi:10.3324/haematol.2022.282252 · Cited by 9
Bock, A. M., Gile, J. J., Larson, M. C., Poonsombudlert, K., Tawfiq, R. K., Maliske, S. M., Maurer, M. J., Kabat, B., Paludo, J., Inwards, D. J., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00942-3 · Cited by 10
Goodstal, S. M., Lin, J., Crandall, T., Crowley, L., Bender, A. T., Pereira, A., Soloviev, M., Wesolowski, J. S., Iadevaia, R., Schelhorn, S.-E., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-47735-z · Cited by 10
Novel agents for mantle cell lymphoma: molecular rational and clinical data
Sarkozy, C., & Ribrag, V. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1760245 · Cited by 10
Song, Y., Wu, S., Shen, Z., Zhao, D., Chan, T. S. Y., Huang, H., Qiu, L., Li, J., Tan, T., Zhu, J., et al. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00448-5 · Cited by 9
Cellular Therapies for Mantle Cell Lymphoma
Yassine, F., Sandoval-Sus, J. D., Ayala, E., Chávez, J. C., Hamadani, M., & Kharfan‐Dabaja, M. A. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.01.026 · Cited by 9
Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells
Wallace, D. S., & Reagan, P. M. (2021) · Drugs · doi:10.1007/s40265-021-01497-y · Cited by 8
Catalytic Asymmetric Synthesis of α‐Arylpyrrolidines and Benzo‐fused Nitrogen Heterocycles
Dai, X., Engl, O. D., León, T., & Buchwald, S. L. (2019) · Angewandte Chemie · doi:10.1002/ange.201814331 · Cited by 8
Recent advances in genomics and therapeutics in mantle cell lymphoma
Lu, T., Zhang, J., McCracken, J., & Young, K. H. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102651 · Cited by 8
Radhakrishnan, V. S., Lokireddy, P., Parihar, M., Prakash, P. S., & Menon, H. (2021) · Cancer Reports · doi:10.1002/cnr2.1590 · Cited by 8
Duminuco, A., Luca, P. D., Stanzione, G., Caruso, L. A., Lavenia, G., Scarso, S., Garibaldi, B., Palumbo, F. E., Vetro, C., & Palumbo, G. A. (2026) · Biomolecules · doi:10.3390/biom16010123 · Cited by 7
Rule, S. A., & Chen, R. W. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1506327 · Cited by 7
Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia
Miao, Y., Xu, W., & Li, J. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1955855 · Cited by 7
Novel treatment for mantle cell lymphoma – impact of BTK inhibitors and beyond
Gribbin, C. K., Chen, J., Martin, P., & Ruan, J. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2264430 · Cited by 7
Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma
Badillo, M., Nava, D., Rosa, M., Chen, W., Guerrero, M. D. C., & Wang, M. L. (2020) · Clinical journal of oncology nursing · doi:10.1188/20.cjon.392-398 · Cited by 7
How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen
Cabeçadas, J., Nava, V. E., Ascensão, J. L., & da Silva, M. G. (2021) · Current Oncology · doi:10.3390/curroncol28060390 · Cited by 7
Novel synthetic drugs for the treatment of non-Hodgkin lymphoma
Manji, F., Puckrin, R., & Stewart, D. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1902988 · Cited by 7
Du, J., Chen, Z., Gu, X.-R., Wang, T., & Huang, Z. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1408983 · Cited by 6
Xie, Y., Zhou, K., Li, L., Liang, A., Mei, H., Zou, D., Li, W., Jin, J., Jin, Z., Jing, H., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015763 · Cited by 6
Ruan, J., Bond, D. A., Shah, B. D., Allan, J. N., Rutherford, S. C., Gribbin, C. K., Chen, Z., Bhinder, B., Tam, W., Rossi, D., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025017760 · Cited by 6
Darnell, E. P., Gallagher, K., Kanska, J. E., Scarfò, I., Balderrama-Gutierrez, G., Berger, T. R., Budka, J. A., Bozym, D. J., Tungsuchat-Huang, T., Shen, R., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025018137 · Cited by 6
Zinzani, P. L., Martelli, M., Ferrero, S., Gentile, M., Laurenti, L., Mauro, F. R., Sportoletti, P., Tedeschi, A., Varettoni, M., & Visco, C. (2022) · Hematological Oncology · doi:10.1002/hon.2983 · Cited by 6
Prognostic Value of Heterogeneity Index Derived from Baseline 18F-FDG PET/CT in Mantle Cell Lymphoma
Liu, F., Gu, B., Li, N., Pan, H., Chen, W., Qiao, Y., Song, S., & Liu, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.862473 · Cited by 6
Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies
Schultze, M. D., & Reeves, D. J. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280231223737 · Cited by 6
Chung, C. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219895079 · Cited by 6
Toxicities of novel therapies for hematologic malignancies
Simon, F., Borrega, J. G., & Bröckelmann, P. J. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1728249 · Cited by 6
Management of Older Adults with Mantle Cell Lymphoma
Romancik, J. T., & Cohen, J. B. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00765-y · Cited by 6
Approach to the Initial Treatment of Older Patients with Mantle Cell Lymphoma
Ruan, J. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.06.005 · Cited by 6
Mantle cell lymphoma: insights into therapeutic targets at the preclinical level
Klener, P. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1813718 · Cited by 5
Wu, M. C., Li, Y., Huang, H., Xu, W., Wang, Y., Huang, H., Zhao, W., Liu, S., Xu, P., Chen, Z., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.770988 · Cited by 6
Evaluation of bleeding events in patients receiving acalabrutinib therapy
Kumar, P. S., Wiczer, T. E., Rosen, L., Pollauf, A. J., Zheng, A., Palettas, M. S., Azali, L., Bhat, S. A., Byrd, J. C., Grever, M. R., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01869-1 · Cited by 6
Forsgren, E., Jørgensen, R. R. K., Bentzen, H., Riise, J., Haaber, J., Pasanen, A., Kuitunen, H. K., Wader, K. F., El‐Galaly, T. C., Hutchings, M., et al. (2025) · HemaSphere · doi:10.1002/hem3.70101 · Cited by 5
Boccellato, E., Comba, L., Tavarozzi, R., Castellino, C., Foglietta, M., Mattei, D. G., Ladetto, M., Massaia, M., & Castellino, A. (2025) · Cancers · doi:10.3390/cancers17132239 · Cited by 5
Clinical management of mantle cell lymphoma in the elderly
Smolewski, P., Rydygier, D., & Robak, T. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1642871 · Cited by 5
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma
Morabito, F., Recchia, A. G., Vigna, E., Botta, C., Skafi, M., Abu-Rayyan, M., Atrash, M., Galimberti, S., Morabito, L., Al‐Janazreh, H., et al. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1689959 · Cited by 5
Alrawashdh, N., McBride, A., Slack, M. K., Persky, D. O., Andritsos, L. A., & Abraham, I. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.4.390 · Cited by 5
What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?
Kumar, A. A. (2022) · Hematology · doi:10.1182/hematology.2022000333 · Cited by 5
Ibrutinib in the management of Waldenstrom macroglobulinemia
Yosef, A., Touloukian, E. Z., & Nambudiri, V. E. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218786037 · Cited by 5
The current role of BTK inhibitors in the treatment of Waldenstrom’s Macroglobulinemia
Gavriatopoulou, M., Fotiou, D., Ntanasis‐Stathopoulos, I., & Dimopoulos, M. A. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1791705 · Cited by 5
Jurczak, W. J., Rule, S. A., Townsend, W. M., Tucker, D. L., Sarholz, B., Scheele, J., Dyroff, M. C., Gribben, J. G., Długosz‐Danecka, M., & Zinzani, P. L. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1913139 · Cited by 5
SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma
Romancik, J. T., Gerber, D. G., Zhuang, T., & Cohen, J. B. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.01.008 · Cited by 5
Stem cell transplant for mantle cell lymphoma in Taiwan
Wang, Y., Hsieh, C.-Y., Hsiao, L., Lin, T.-L., Liu, Y., Yao, M., Tan, T., & Ko, B. (2022) · Scientific Reports · doi:10.1038/s41598-022-09539-5 · Cited by 5
Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease
Tarockoff, M., Gonzalez, T., Ivanov, S., & Sandoval-Sus, J. D. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01297-x · Cited by 5
Evolving treatment strategies in mantle cell lymphoma
Edwin, N. C., & Kahl, B. S. (2018) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2018.07.005 · Cited by 5
Vorobyev, V. I., Гемджян, Э. Г., Dubrovin, E. I., Nesterova, E., Kaplanov, K. D., Volodicheva, E. M., Анатольевна, Ж. В., & Кравченко, С. К. (2019) · Terapevticheskii arkhiv · doi:10.26442/00403660.2019.07.000322 · Cited by 5
Risk of infection associated with new therapies for lymphoproliferative syndromes
Arcos, I. L., & Ruíz-Camps, I. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2019.07.006 · Cited by 5
Idárraga, J. A. O., Martínez‐Cordero, H., Idrobo, H., Alfaro, C. O., Correa, L. M. M., Garcia, J. E., Malpica, L., Castillo, J. J., Viera, M. T., Villela, L., et al. (2020) · Revista Colombiana de Cancerología · doi:10.35509/01239015.690 · Cited by 5
Kim, M. S., Banerjee, T., Chen, A., Danilov, A. V., MacKinnon, R., Thurlow, B. L., Thakurta, S., Orand, K., Degnin, C., Park, B. S., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2045598 · Cited by 4
Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia
Tawfiq, R. K., Abeykoon, J. P., & Kapoor, P. (2024) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-024-00731-0 · Cited by 4
Advances in the treatment of mantle cell lymphoma with BTK inhibitors
Shen, J., Li, J., Yang, R., Wu, S., Mu, Z., Ding, S., Zhang, X., Duo, M., Chen, Y., & Liu, J. (2024) · Leukemia Research · doi:10.1016/j.leukres.2024.107615 · Cited by 4
Trab, T., Chanchiri, I., Al‐Mashhadi, A. L., Dall, E. B., Rasch, S., Johansen, M., Husby, S., Simonsen, M. R., Clausen, M. R., Larsen, T. S., et al. (2025) · Blood Neoplasia · doi:10.1016/j.bneo.2025.100128 · Cited by 4
Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma
Sharp, J., Shana’ah, A. Y., Voorhees, T. J., Bond, D. A., Sawalha, Y., Sigmund, A. M., Hanel, W. G., Sehgal, L., Alinari, L., Baiocchi, R. A., et al. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2025.7045 · Cited by 4
The safety of Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A systematic review
Arustamyan, M., Kibrik, P., Hatipoğlu, D., Bungo, B., Mentias, A. G., Hill, B. T., & Moudgil, R. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13854 · Cited by 4
Ito, D., Feng, C., Fu, C. T., Kim, C., Wu, J. J., Epstein, J., Snider, J. T., & DuVall, A. S. (2023) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2023.2216458 · Cited by 4
Lage, L. A. D. P. C., Elias, M. D. V., Reichert, C. O., Culler, H. F., de Freitas, F. A., Costa, R. O., Rocha, V., Siqueira, S. A. C., & Pereira, J. C. (2023) · Cancers · doi:10.3390/cancers15194759 · Cited by 4
Management of relapsed/refractory mantle cell lymphoma
Alzahrani, M. F., & Villa, D. R. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2338851 · Cited by 4
Barraclough, A., Tang, C., Lasica, M., Smyth, E., Cirillo, M., Mutsando, H., Cheah, C. Y., & Ku, M. (2024) · Internal Medicine Journal · doi:10.1111/imj.16561 · Cited by 4
Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia
Fatima, N., Crassini, K. R., Thurgood, L. A., Shen, Y., Christopherson, R. I., Kuss, B. J., Mulligan, S. P., & Best, G. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2019.111 · Cited by 4
The safety of available chemo-free treatments for mantle cell lymphoma
Korycka, A., Wołowiec, D., & Robak, T. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1826435 · Cited by 4
Davis, J. A., Graham, A., Hendrickson, L., Hess, B. T., & Gaffney, K. J. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2056179 · Cited by 4
Yohannan, B., Sridhar, A., Nguyen, N., & Rios, A. A. (2022) · BMJ Case Reports · doi:10.1136/bcr-2022-249631 · Cited by 4
Treatment of older patients with mantle cell lymphoma in the era of novel agents
Rozental, A., Jim, H., & Extermann, M. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2227748 · Cited by 4
Squires, P. J., Puckett, J. T., Ryland, K. E., Kamal‐Bahl, S. J., Raut, M. K., Doshi, J. A., & Huntington, S. F. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2234525 · Cited by 4
Li, S. J., Hao, J., Mao, Y., & Si, Y.-L. (2019) · Turkish Journal of Hematology · doi:10.4274/tjh.galenos.2019.2019.0128 · Cited by 4
Sequencing of Novel Therapies for Mantle Cell Lymphoma
Romancik, J. T., & Cohen, J. B. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00907-3 · Cited by 4
Advances and resistance adaptation in BTK-targeted therapy for B-cell malignancies
Yang, S., Oh, J., Hwang, S.-Y., Paik, J., & Hwang, I. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101383 · Cited by 3
Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma
Gopalsamy, S. N., Rosenthal, K. M., Ayers, A. A., Goy, A. H., Leonard, J. P., Vose, J. M., Obholz, K. L., Armitage, J. O., & Flowers, C. R. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1574006 · Cited by 3
How to treat older patients with mantle cell lymphoma in the era of targeted drugs
Robak, T., & Robak, P. J. (2022) · Annals of Palliative Medicine · doi:10.21037/apm-22-345 · Cited by 3
[The guideline of the diagnosis and treatment of mantle cell lymphoma in China (2022)].
(2022) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2022.07.001 · Cited by 3
Song, Y., Li, J., Zhou, K., Ke, X., Cai, Z., Zhang, H., Yao, T., Xia, Z., Wang, Y., Lai, P., et al. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2310141 · Cited by 3
Does TRIANGLE take down transplantation in mantle cell lymphoma?
Martin, P., & Maddocks, K. J. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00301-5 · Cited by 3
Challenges of treating mantle cell lymphoma in older adults
Munoz, J. L., Tsang, M., Wang, Y., & Phillips, T. J. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2431563 · Cited by 3
Filioglou, D., Santa-Cruz, N., Leite, G. S., Davini, D. W., Cracchiolo, M. J., Baker, F. L., Husnain, M., Simpson, R. J., Voudouris, V., & Katsanis, E. (2025) · Cancers · doi:10.3390/cancers17111889 · Cited by 3
Is Limited-Stage Mantle Cell Lymphoma Curable and How Is It Best Managed?
Romancik, J. T., & Cohen, J. B. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.06.003 · Cited by 3
Incorporating Novel Targeted and Immunotherapeutic Agents in the Treatment of B-Cell Lymphomas
Shah, H., Stephens, D. M., Seymour, J. F., & Maddocks, K. J. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320117 · Cited by 3
Metadata
- Authors
- Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., Damaj, G., Doorduijn, J., Lamy, T., Morschhauser, F., Panizo, C., Shah, B., Davies, A., Eek, R., Dupuis, J., Jacobsen, E., Kater, A. P., Le Gouill, S., Oberic, L., Robak, T., Covey, T., Dua, R., Hamdy, A., Huang, X., Izumi, R., Patel, P., Rothbaum, W., Slatter, J. G., & Jurczak, W.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of Plymouth (GB)
- University of Bologna (IT)
- Hackensack University Medical Center (US)
- Inserm (FR)
- University of Washington (US)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Erasmus MC (NL)
- Centre Hospitalier Universitaire de Rennes (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Clinica Universidad de Navarra (ES)
- Moffitt Cancer Center (US)
- Cancer Research UK (GB)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Harvard University (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- Jagiellonian University (PL)
- Corresponding author
- Wang, Michael
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 391
- Issue
- 10121
- Pages
- 659-667
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC7864374
- OpenAlex
- W2774522106
- Cited by
- 453
- References
- 23
- Citations by year
- 2026: 39 · 2025: 31 · 2024: 51 · 2023: 49 · 2022: 59 · 2021: 60 · 2020: 63 · 2019: 64 · 2018: 34
- FWCI
- 34.80
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- PEARL (University of Plymouth) (submittedVersion, other-oa)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- HAL (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
- ePrints Soton (University of Southampton) (submittedVersion)
- PEARL (University of Plymouth) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- AstraZeneca
- University of Texas MD Anderson Cancer Center
- National Cancer Institute (P30CA076292)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Keywords
- acalabrutinib, mantle cell lymphoma, relapsed/refractory lymphoma, BTK inhibitors, overall response rate, complete response, progression-free survival, overall survival, adverse events, neutropenia, drug safety, oral targeted therapy, treatment durability, hemorrhage
- MeSH terms
- Aged, Benzamides, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Pyrazines, Recurrence, Survival Analysis, Treatment Outcome, Lymphoma, Mantle-Cell, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
